Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial

BACKGROUND. Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JCI Insight
Главные авторы: Consolim-Colombo, Fernanda M., Sangaleti, Carine T., Costa, Fernando O., Morais, Tercio L., Lopes, Heno F., Motta, Josiane M., Irigoyen, Maria C., Bortoloto, Luiz A., Rochitte, Carlos Eduardo, Harris, Yael Tobi, Satapathy, Sanjaya K., Olofsson, Peder S., Akerman, Meredith, Chavan, Sangeeta S., MacKay, Meggan, Barnaby, Douglas P., Lesser, Martin L., Roth, Jesse, Tracey, Kevin J., Pavlov, Valentin A.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2017
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518569/
https://ncbi.nlm.nih.gov/pubmed/28724799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93340
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы